Xtremity, a premium medical device brand that develops advanced prosthetic socket technology, today announced closing of a Series B3 financing round, totaling $8.1 million with strong insider participation and the addition of several prominent new investors. The cash infusion will support establishing Xtremity as a leading developer and provider of advanced prosthetic technologies by bringing its first product, an innovative transtibial prosthetic socket, the XtremityTT, to market.
“Xtremity was formed to re-envision prosthetic development and to transform care for individuals living with limb loss or limb difference,” said Maynard Carkhuff, president and chief executive officer at Xtremity. “With a mission to enhance the patient experience, Xtremity is introducing the first and only socket on the market that enables rapid fabrication and future adjustability; this financing will be crucial in launching XtremityTT and expanding our company.”
